Adolescent and Adult Vaccines Market 2018 Report at RnR Market Research

The leading business intelligence provider GBI Research has released its latest research report, entitled “Adult and Adolescent Vaccines Market to 2018”. The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market, as well as insights into the adult and adolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccines market. The report analyzes the market for adult and adolescent vaccines in the US, and the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report discusses the global pipeline for adult and adolescent vaccines across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the adult and adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. The market is projected to witness a growth of 5.6% during the 2011–2018 forecast period to reach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcal vaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in 2011.

Get Complete Report Details @ http://www.rnrmarketresearch.com/adult-and-adolescent-vaccines-market-to-2018-promising-novel-candidates-in-late-stage-development-and-prevnar-approval-for-use-in-adults-to-drive-growth-market-report.html

Scope

- Annualized market data for the adult and adolescent vaccines market from 2007 to 2011, forecast forward to 2018

- Analysis of the adult and adolescent vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the adult and adolescent vaccines market including market size and cost of vaccination

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of vaccine development

- Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.

- Key M&A activities and licensing agreements that have taken place between 2009 and up to November 2012 in the global adult and adolescent vaccines market.

Reasons to Buy

- Align your product portfolio to the markets with the highest growth potential

- Develop market-entry and market expansion strategies by identifying the potential regions and adult and adolescent vaccines market segments poised for strong growth

- Create a more specifically-tailored country strategy through the understanding of key drivers and barriers of the global adult and adolescent vaccines market

- Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=88539

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Adult and Adolescent Vaccines Market to 2018: Introduction
2.1 Overview

3 Adult and Adolescent Vaccines Market to 2018: Overview
3.1 Vaccine Preventable Diseases
3.1.1 Types of Vaccines
3.2 Recommendations for Immunization
3.2.1 The US
3.2.2 Top Five European Countries
3.2.3 Japan
3.3 Regulatory Framework
3.3.1 The US
3.3.2 Top Five European Countries
3.3.3 Japan
3.4 Vaccine Manufacturing Process

4 Adult and Adolescent Vaccines Market to 2018: Market Characterization and Forecast
4.1 Revenue Forecast
4.2 Market Share by Type of Vaccines
4.3 Market Share by Geography
4.4 Drivers
4.4.1 Adult Vaccines Segment to Drive Future Growth
4.4.2 High Unmet Needs
4.4.3 Targeting New Diseases Areas for Vaccines Likely To Drive the Market
4.4.4 Novel Vaccine Technologies
4.5 Restraints
4.5.1 Production Capacity Limitations
4.5.2 High Initial Capital Investments and Technical Expertise
4.5.3 Regulations Delay Vaccine Launch and Acceptance

5 Adult and Adolescent Vaccines Market to 2018: Influenza Vaccines
5.1 Disease Overview
5.2 Market Forecasts
5.2.1 The US
5.2.2 Top Five European Countries
5.2.3 Japan
5.3 Cost of Vaccination
5.3.1 The US
5.3.2 Top Five European Countries
5.3.3 Japan
5.4 Pipeline Analysis – Influenza Vaccines

6 Adult and Adolescent Vaccines Market to 2018: Tetanus, Diphtheria and Pertussis Vaccines
6.1 Disease Overview
6.2 Market Forecasts
6.2.1 The US
6.2.2 Top Five European Countries
6.2.3 Japan
6.3 Cost of Vaccination
6.3.1 The US
6.3.2 Top Five European Countries
6.3.3 Japan
6.4 Pipeline Analysis – Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccines

7 Adult and Adolescent Vaccines Market to 2018: Pneumococcal Vaccines
7.1 Disease Overview
7.2 Market Forecasts
7.2.1 The US
7.2.2 Top Five European Countries
7.2.3 Japan
7.3 Cost of Vaccination
7.3.1 The US
7.3.2 Top Five European Countries
7.3.3 Japan
7.4 Pipeline Analysis – Pneumococcal Vaccines

8 Adult and Adolescent Vaccines Market to 2018: Meningococcal Vaccines
8.1 Disease Overview
8.2 Market Forecasts
8.2.1 The US
8.2.2 Top Five European Countries
8.3 Cost of Vaccination
8.3.1 The US
8.3.2 Top Five European Countries
8.4 Pipeline Analysis – Meningococcal Vaccines

9 Adult and Adolescent Vaccines Market to 2018: Human Papilloma Virus Vaccines
9.1 Disease Overview
9.2 Market Forecasts
9.2.1 The US
9.2.2 Top Five European Countries
9.2.3 Japan
9.3 Cost of Vaccination
9.3.1 The US
9.3.2 Top Five European Countries
10 Adult and Adolescent Vaccines Market to 2018: Hepatitis Vaccines
10.1 Disease Overview
10.2 Market Forecasts
10.2.1 The US
10.2.2 Top Five European Countries
10.2.3 Japan
10.3 Cost of Vaccination
10.3.1 The US
10.3.2 Top Five European Countries
11 Adult and Adolescent Vaccines Market to 2018: Measles, Mumps and Rubella Vaccines
11.1 Disease Overview
11.2 Market Forecasts
11.2.1 The US
11.2.2 Top Five European Countries
11.2.3 Japan
11.3 Cost of Vaccination
11.3.1 The US
11.3.2 Top Five European Countries
11.3.3 Japan

12 Adult and Adolescent Vaccines Market to 2018: Zoster Vaccines
12.1 Disease Overview
12.2 Market Forecasts
12.2.1 The US
12.2.2 The UK
12.3 Cost of Vaccination
12.3.1 The US
12.3.2 The UK
12.4 Pipeline Analysis – Zoster Vaccines

13 Adult and Adolescent Vaccines Market to 2018: Varicella Vaccines
13.1 Disease Overview
13.2 Market Forecasts
13.2.1 The US
13.2.2 Top Five European Countries
13.2.3 Japan
13.3 Cost of Vaccination
13.3.1 The US
13.3.2 Top Five European Countries
13.3.3 Japan
13.4 Pipeline Analysis – Varicella Vaccines

14 Adult and Adolescent Vaccines Market to 2018: Competitive Landscape
14.1 Introduction
14.2 Major Company Profiles
14.2.1 GlaxoSmithKline
14.2.2 Sanofi
14.2.3 Pfizer
14.2.4 Merck
14.2.5 Novartis
15 Adult and Adolescent Vaccines Market to 2018: Strategic Consolidations
15.1 Deals by Year
15.2 Deals by Type
15.3 Deals by Value
15.4 Deals by Geography
15.5 Summary of Major M&A Deals
15.6 Summary of Major Licensing Deals
15.7 Summary of Major Partnerships

16 Adult and Adolescent Vaccines Market to 2018: Appendix
16.1 Market Definitions
16.2 Abbreviations
16.3 Bibliography
16.4 Research Methodology
16.4.1 Coverage
16.4.2 Secondary Research
16.4.3 Primary Research
16.4.4 Model for Estimation of Vaccine Market
16.5 Geographical Landscape
16.6 Pipeline Analysis